Sonnet BioTherapeutics Holdings Future Growth
Future criteria checks 2/6
Sonnet BioTherapeutics Holdings's earnings are forecast to decline at 24.8% per annum while its annual revenue is expected to grow at 69.1% per year.
Key information
-24.8%
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 23.2% |
| Revenue growth rate | 69.1% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 12 Mar 2024 |
Recent future growth updates
Recent updates
Sonnet BioTherapeutics regains compliance with Nasdaq's minimum bid price requirement
Oct 04Sonnet BioTherapeutics announces 1-for-14 reverse stock split
Sep 16Sonnet gets clearance to start phase 1b/2a trial of SON-080 in Australia
Jul 22We're A Little Worried About Sonnet BioTherapeutics Holdings' (NASDAQ:SONN) Cash Burn Rate
Dec 19
Sonnet Bio issued U.S. patent for its albumin binding technology
Jun 08Sonnet shares rise after completing licensing agreement with New Life Therapeutics
May 03Sonnet BioTherapeutics reports FY results
Dec 17Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2026 | N/A | -28 | -28 | N/A | 1 |
| 9/30/2025 | N/A | -21 | -21 | N/A | 1 |
| 9/30/2024 | 0 | -7 | -13 | N/A | 4 |
| 12/31/2023 | 0 | -14 | -19 | -19 | N/A |
| 9/30/2023 | 0 | -19 | -22 | -21 | N/A |
| 6/30/2023 | 0 | -23 | -23 | -23 | N/A |
| 3/31/2023 | 0 | -27 | -25 | -25 | N/A |
| 12/31/2022 | 0 | -29 | -26 | -26 | N/A |
| 9/30/2022 | 0 | -30 | -29 | -28 | N/A |
| 6/30/2022 | 1 | -29 | -28 | -27 | N/A |
| 3/31/2022 | 1 | -27 | -26 | -25 | N/A |
| 12/31/2021 | 1 | -25 | -26 | -26 | N/A |
| 9/30/2021 | 0 | -25 | -23 | -23 | N/A |
| 6/30/2021 | N/A | -67 | -22 | -22 | N/A |
| 3/31/2021 | N/A | -73 | -23 | -23 | N/A |
| 12/31/2020 | N/A | -69 | -19 | -19 | N/A |
| 9/30/2020 | N/A | -66 | -16 | -16 | N/A |
| 6/30/2020 | N/A | -20 | -11 | -11 | N/A |
| 3/31/2020 | N/A | -9 | -5 | -5 | N/A |
| 12/31/2019 | N/A | -7 | -4 | -4 | N/A |
| 9/30/2019 | N/A | -5 | -2 | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SONN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SONN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SONN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SONN's revenue (69.1% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: SONN's revenue (69.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SONN's Return on Equity is forecast to be high in 3 years time